The present results identified topographies of tau deposition as measured by T807 PET imaging that were associated with clinical status, Aβ deposition as revealed by PET imaging, CSF AD biomarkers, and AD-related cognitive impairment. This evidence concerns the gene MAPT and Alzheimer disease.